Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astellas pharma europe b.v. - tacrolimus - rifjut ta 'graft - immunosoppressanti - profilassi tar-rifjut tat-trapjant f'reċipjenti adulti u pedjatriċi, tal-kliewi, tal-fwied jew tal-alloġib tal-qalb. it-trattament tal-allograft rifjut reżistenti għall-kura bi prodotti mediċinali immunosuppressivi oħra f'pazjenti adulti u pedjatriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - virus tal-influwenza maqsuma, inattivat, li fih antiġen: razza użata bħala a / vietnam / 1194/2004 (h5n1) użata (nibrg-14) - influenza, human; immunization; disease outbreaks - vaċċini - profilassi tal-influwenza f'sitwazzjoni pandemika ddikjarata uffiċjalment. il-vaċċin kontra l-influwenza pandemika għandu jintuża skond il-gwida uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - qasma-virus tal-influwenza, inattivat, li fih antiġen*:/california/7/2009 (h1n1)v like strain (x-179a)*propagati fil-bajd. - influenza, human; immunization; disease outbreaks - vaċċini ta 'l-influwenza - profilassi tal-influwenza f'sitwazzjoni pandemika ddikjarata uffiċjalment. il-vaċċin kontra l-influwenza pandemika għandu jintuża skond il-gwida uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - vaċċini ta 'l-influwenza - profilassi tal-influwenza kkawżata mill-virus a (h1n1v) 2009. focetria għandu jintuża skont il-gwida uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

seqirus s.r.l.  - antiġeni tal-wiċċ tal-virus ta 'l-influwenza, inattivati: a / vjet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaċċini ta 'l-influwenza - profilassi tal-influwenza f'sitwazzjoni pandemika ddikjarata uffiċjalment. il-vaċċin kontra l-influwenza pandemika għandu jintuża skond il-gwida uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur s.a. - qasma-virus tal-influwenza, inattivat, li fih antiġen*:/california/7/2009 (h1n1)v like strain (x-179a)*propagati fil-bajd. - influenza, human; immunization; disease outbreaks - vaċċini - profilassi tal-influwenza f'sitwazzjoni pandemika ddikjarata uffiċjalment. vaċċin għal influwenza pandemika għandu jintuża skont il-gwida uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur s.a. - virus tal-influwenza (inattivat, maqsuma) tar-razez li ġejjin:/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, tat-tip selvaġġ) - influenza, human; immunization - vaċċini - profilassi ta 'l-influwenza f'individwi ta' 60 sena jew aktar, speċjalment f'dawk li għandhom riskju akbar ta 'kumplikazzjonijiet assoċjati. l-użu ta ' idflu għandu jkun ibbażat fuq rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , l-effett ta ' imatinib fuq l-eżitu tal-trapjant tal-mudullun għadu ma ġiex determinat. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. l-esperjenza b'imatinib f'pazjenti b'mds/mpd assoċjati ma ' tibdil fil-ġene pdgfr hija limitata ħafna. m'hemmx provi kliniċi li juru benefiċċju kliniku jew żieda fis-sopravivenza għal dawn il-mard.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zoetis belgium sa - dibotermin alfa - proteini morfogenetiċi għall-għadam - klieb - aġent osteoindużiv għall-użu fit-trattament ta 'ksur tal-għadam fit-tul bħala addizzjoni għal kura kirurġika standard bl-użu ta' tnaqqis fil-fratturi miftuħ fil-klieb.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur europe - virus tal-influwenza (inattivat, maqsuma) tar-razez li ġejjin:/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, tat-tip selvaġġ) - influenza, human; immunization - vaċċini - profilassi ta 'l-influwenza f'individwi ta' 60 sena jew aktar, speċjalment f'dawk li għandhom riskju akbar ta 'kumplikazzjonijiet assoċjati. l-użu ta ' intanza għandu jkun ibbażat fuq rakkomandazzjonijiet uffiċjali.